Expert urologist Naveen Kella, MD, shares his perspective on the advent of PSMA PET-CT imaging in patients with prostate cancer, addressing both benefits and limitations to this approach.
Phase 1B trial to evaluate relugolix and enzalutamide in high-risk prostate cancer
July 24th 2024"Going forward after this study, we hope to be able to expand and potentially look at patients undergoing either surgery or radiation therapy, and really try to determine the potential benefit," says Kelly L. Stratton, MD, FACS.